Interleukin-2-IgM

Drug Profile

Interleukin-2-IgM

Latest Information Update: 28 Nov 2007

Price : $50

At a glance

  • Originator INSERM
  • Class Interleukins
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hypersensitivity; Transplant rejection

Most Recent Events

  • 10 Jan 1996 Preclinical development for Allergy in France (Unknown route)
  • 06 Jan 1995 Preclinical development for Transplant rejection in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top